Lv1
70 积分 2024-05-10 加入
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
14小时前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
20天前
已完结
Exploiting the folate receptor α in oncology
1个月前
已完结
Evolution of low HER2 expression between early and advanced-stage breast cancer
2个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
2个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2个月前
已完结
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
4个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
5个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
5个月前
已完结
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management
6个月前
已完结
皖公网安备34019202002308
